Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy
PHASE2CompletedINTERVENTIONAL
Enrollment
55
Participants
Timeline
Start Date
Not specified
Conditions
Follicular Lymphoma
Interventions
DRUG
FM+R
Fludarabine-Mitoxantrone-Rituximab
DRUG
Zevalin (Ibritumomab Tiuxetan)
Trial Locations (1)
40138
Istituto di Ematologia e Oncologia Medica Seràgnoli, Bologna
All Listed Sponsors
lead
University of Bologna
OTHER
NCT00859001 - Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy | Biotech Hunter | Biotech Hunter